• 1
    Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 24932505.
  • 2
    Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428434.
  • 3
    Fernández-Rodríguez CM, López-Serrano P, Alonso S et al. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 2006; 24: 507512.
  • 4
    Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C infection in the United States. Ann Intern Med 2000; 133: 592599.
  • 5
    Mehta SH, Brancati FL, Strathdee SA et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 5056.
  • 6
    Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 70757080.
  • 7
    Romero-Gomez M, Dek Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636641.
  • 8
    Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721727.
  • 9
    Kawaguchi T, Ide T, Taniguchi E et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570576.
    Direct Link:
  • 10
    Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 23752414.
  • 11
    Galli M, Polo R, Saint-Marc T et al. for the ART-Associated Lipodystrophy European Collaborative Study (ALECS) Group. Proposal for a clinic classification of morphological and metabolic alterations under ART. Antiviral Ther 2000; 5 (Suppl. 5): 57. Abstract P58.
  • 12
    Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 13171325.
  • 13
    Nasta P, Gatti F, Puoti M et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 2008; 22: 857861.
  • 14
    Gopal K, Johnson TC, Gopal S et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335340.
  • 15
    Akuta N, Suzuki F, Kawamura Y et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels 1b. J Hepatol 2007; 46: 403410.
  • 16
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438450.
  • 17
    Knobler H, Schattner A. TNF-α, chronic hepatitis C and diabetes: a novel triad. Quart J Med 2005; 98: 16.
  • 18
    Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 14991508.
  • 19
    Dharancy S, Malapel M, Perlemuter G et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334342.
  • 20
    Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract 2007; 75: 320326.
  • 21
    Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med 2008; 3: 99108.
  • 22
    Wand H, Calmy A, Carey DL et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21: 24452453.
  • 23
    Lo JC, Kazemi MR, Hsue PY et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 2005; 41: 13351340.
  • 24
    Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51F58.
  • 25
    Lapadula G, Torti C, Paraninfo G et al. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther 2006; 11: 521527.
  • 26
    Bedimo R, Ghurani R, Nsuami M et al. Lipid abnormalities in HIV/hepatitis C virus-coinfected patients. HIV Med 2006; 7: 530536.
  • 27
    Galli M, Cozzi-Lepri A, Ridolfo AL et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med 2002; 162: 26212628.
  • 28
    Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997; 157: 792796.
  • 29
    Agnello V, Abel G, Elfahal M, Knight GB, Zhang OX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 1276612771.
  • 30
    André P, Komurian-Pradel F, Deforges S et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 69196928.